A Broad-Spectrum Mechanism to Address Life-Threatening Targets

Sigyn Therapy is a dual-function blood purification technology that extracts pathogen sources of life-threatening inflammation in concert with the broad-spectrum elimination of inflammatory mediators that fuel sepsis.

Since December of 2020, a series of invitro blood purification studies have validated the ability of Sigyn Therapy to address endotoxin (a gram-negative bacterial toxin), peptidoglycan and lipoteichoic acid (gram-positive bacterial toxins), viral pathogens (including COVID-19), hepatic toxins (ammonia, bile acid & bilirubin), cytovesicles that transport inflammatory cargos, and relevant proinflammatory cytokines (TNF-a, IL-1b, IL-6) that underlie the cytokine storm that precipitates sepsis.

An Expansive Treatment Pipeline

The pathogen-related opportunities for Sigyn Therapy include but are not limited to the treatment of emerging bioterror and pandemic threats, drug-resistant pathogens (including antibiotic-resistant bacterial infections), hepatic encephalopathy and community-acquired pneumonia (CAP). CAP is a leading cause of death among infectious diseases, the leading cause of death in children under 5 years of age, and a catalyst for ~50% of sepsis and septic shock cases.

 

View Therapeutic Opportunities

Sigyn Therapy Highlights

  • We designed Sigyn Therapy to perform functions that are beyond the reach of drugs and to overcome the constraints of blood purification technologies that are limited to the individual targeting of either cytokines, endotoxin, or viruses.
  • Sigyn Therapy is a single-use disposable device that can be deployed for use on the established infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines located in hospitals and clinics worldwide.
  • To optimize the extraction of bloodstream targets, Sigyn Therapy incorporates a formulation of adsorbent components that provide more than 200,000 square meters (~50 acres) of surface area on which to adsorb and remove bloodstream targets.
  • Unlike devices that concentrate therapeutic targets in the blood-path, Sigyn Therapy extracts targets from the bloodstream, which eliminates their ability to interact with blood cells during treatment.